Sort by
A Risk-Driven Maritime Patrol Route Optimization Framework for IUU Fishing Surveillance Using Multi-Source AIS and SAR Data Fusion
Songtao Hu
,Qianyue Zhang
,Yiming Wang
,Xiaokang Wang
Posted: 14 April 2026
How Sustainable Corporate Social Responsibility Shapes Brand Citizenship Behavior: The Mediating Role of Brand Reliability and the Moderating Role of Corporate Social Responsibility Skepticism
Aysun Varan
,Aslıhan Bekaroğlu Özatar
Posted: 14 April 2026
Modulating the Gut Microbiome in Obesity: Interventions and Clinical Implications
Shruti Pai
Posted: 14 April 2026
Beyond Digitization: The Need for Inclusive Co-Governance in Reforming Indian Land Administration
Madhushree Sekher
,Menokhono
,Bill Pritchard
,Shraddha Vikas
,Balbir Singh Aulakh
Posted: 14 April 2026
A Retrospective Study Evaluating the Efficacy and Safety of Oral Semaglutide Compared to Injectables in Controlling Diabetes and Weight Reduction
Zabih Ullah
,Hind Khalid Goresh
,Sultan Hassan Almarwani
,Mabrouk Alrashidi
,Aymen Hassan D Almarwani
,Monadil Hassan
,Ghaleb Alharbi
,Ali Muhammad Salem Alharbi
,Sulaiman Ibrahim Alsohaim
,Jayiz S Alharbi
Objective: To compare the efficacy, safety, weight reduction and treatment adherence of oral versus subcutaneous semaglutide in adults with uncontrolled T2DM and obesity. Methods: A multicenter retrospective cohort study was conducted between January 2023 and January 2024. Adult patients (≥18 years) with T2DM (HbA1c ≥ 7%) and obesity (BMI ≥ 30) who received either oral or subcutaneous semaglutide were included. Demographic, clinical, and biochemical variables including body weight, BMI, HbA1c, side effects, and adherence were extracted from electronic medical records. Adverse effects were categorized by severity. Comparative analyses between groups used Chi-square and Mann Whitney U tests, with p<0.05 considered statistically significant. Results: A total of 208 patients were included: 89 on oral semaglutide and 119 on subcutaneous semaglutide. Baseline demographics, including gender, age, and physical activity, were comparable between groups (all p>0.05). The severity of adverse effects predominantly gastrointestinal symptoms such as nausea, vomiting, constipation, and diarrhea did not differ significantly between groups (p=0.994). However, dizziness was significantly more frequent in the subcutaneous group (p = 0.04). Adherence was markedly higher with oral semaglutide (p<0.05), with cost identified as the primary barrier among oral users, while subcutaneous users more frequently cited side effects, forgetfulness, and limited weight loss. Weight reduction was comparable at 3 months (p=0.23), but significantly greater with oral semaglutide at 6, 9, and 12 months (all p<0.01). Conversely, HbA1c reduction favored subcutaneous semaglutide at 3 and 6 months (p=0.03 and 0.02), although baseline glycemic control was similar. Conclusions: This study demonstrates that while subcutaneous semaglutide may provide a faster early HbA1c decline, oral semaglutide offers superior long-term weight reduction and significantly better adherence, likely attributable to easier administration. Both formulations exhibited comparable safety profiles.
Objective: To compare the efficacy, safety, weight reduction and treatment adherence of oral versus subcutaneous semaglutide in adults with uncontrolled T2DM and obesity. Methods: A multicenter retrospective cohort study was conducted between January 2023 and January 2024. Adult patients (≥18 years) with T2DM (HbA1c ≥ 7%) and obesity (BMI ≥ 30) who received either oral or subcutaneous semaglutide were included. Demographic, clinical, and biochemical variables including body weight, BMI, HbA1c, side effects, and adherence were extracted from electronic medical records. Adverse effects were categorized by severity. Comparative analyses between groups used Chi-square and Mann Whitney U tests, with p<0.05 considered statistically significant. Results: A total of 208 patients were included: 89 on oral semaglutide and 119 on subcutaneous semaglutide. Baseline demographics, including gender, age, and physical activity, were comparable between groups (all p>0.05). The severity of adverse effects predominantly gastrointestinal symptoms such as nausea, vomiting, constipation, and diarrhea did not differ significantly between groups (p=0.994). However, dizziness was significantly more frequent in the subcutaneous group (p = 0.04). Adherence was markedly higher with oral semaglutide (p<0.05), with cost identified as the primary barrier among oral users, while subcutaneous users more frequently cited side effects, forgetfulness, and limited weight loss. Weight reduction was comparable at 3 months (p=0.23), but significantly greater with oral semaglutide at 6, 9, and 12 months (all p<0.01). Conversely, HbA1c reduction favored subcutaneous semaglutide at 3 and 6 months (p=0.03 and 0.02), although baseline glycemic control was similar. Conclusions: This study demonstrates that while subcutaneous semaglutide may provide a faster early HbA1c decline, oral semaglutide offers superior long-term weight reduction and significantly better adherence, likely attributable to easier administration. Both formulations exhibited comparable safety profiles.
Posted: 14 April 2026
Legitimacy Stress-Testing AI–IoT Climate Adaptation: Contextual Validity and Incident Evaluation in Water Systems
Victor Frimpong
Posted: 14 April 2026
Predicting Long-Term Biological Dynamics from Early-Time State-Space Geometry
Arturo Tozzi
Posted: 14 April 2026
Suction Impact on Chest Drain Duration After Lung Resection: A Study Using Digital Drainage Systems
Dan Levy Faber
,Juna Azizi
,Ronen Galili
,Sonia Schneer
,Abed Agbarya
Posted: 14 April 2026
Democritus: Inferring Causality from Language
Sridhar Mahadevan
Posted: 14 April 2026
Nursery Tree Trait Preferences Among Florida (United States) Homeowners
Andrew Koeser
,Taylor Sherer
,Ryan Klein
,John Roberts
Posted: 14 April 2026
Feature Transformer and LightGBM Ensemble for Ship Trajectory Recognition Using Real AIS Data
Songtao Hu
,Liang Chen
,Qianyue Zhang
,Wenchao Liu
Posted: 14 April 2026
Optimization and Characterization of Polymeric Microneedle Patches for Enhanced Transdermal Delivery of Cyanocobalamin
Prashant Saraswat
,Abhinav Agarwal
,Vijay Agarwal
,Nitin Kumar
Posted: 14 April 2026
A Hybrid Graph–Markov Model for Workload Generation in Load Testing
Dara Surya Varaprakash
Posted: 14 April 2026
Gyromagnetic Ratio of Electrically Neutral Particles: Case of the Neutron
Golden Gadzirayi Nyambuya
Posted: 14 April 2026
AgentVerify: Compositional Formal Verification of AI Agent Safety Properties via LTL Model Checking
Eric Fang
Posted: 14 April 2026
Assessment of the Environmental Impacts of the Launch of the “Soyuz-2.1a” Launch Vehicle with the “Progress MS-29” Cargo Spacecraft in Kazakhstan
Aliya Kalizhanova
,Murat Kunelbayev
,Anar Utegenova
,Ainur Kozbakova
,Serik Daruish
Posted: 14 April 2026
Classifying Consensus Sequences Using Point-Set Representations
Jason Shulman
,Preethi H. Gunaratne
,Gemunu H. Gunaratne
Posted: 14 April 2026
Beyond Stenosis: Mechanism-Based Multimodality Imaging and Invasive Coronary Function Testing for Endotype Definition in ANOCA/INOCA
Lucio Giuseppe Granata
,Marcello Marchetta
,Simona Giubilato
,Giuseppe Massimo Sangiorgi
,Giuseppina Maura Francese
,Giuseppe Andò
Posted: 14 April 2026
A Traffic Sign Detection Algorithm Based on an Improved YOLOv8n
Yanyan Jia
,Siyi Wang
Posted: 14 April 2026
Preparation of Mono- and Bivalent (Bis) Prostate-Specific Membrane Antigen (PSMA) Ligands and Their Preclinical Investigation as PET Imaging Agents for PSMA-Receptor Positive Prostate Cancer
Subhani M. Okarvi
Posted: 14 April 2026
of 5,795